Implications of genetic polymorphisms in inflammation-induced atherosclerosis

Open Cardiovascular Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2010, Pages 30-37

  Shanker, Jayashree ^a   Kakkar, Vijay V ^a,b  

^a THROMBOSIS RESEARCH INSTITUTE   (India)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Atherosclerosis; Biomarkers; Genes; Inflammation; REFERENCES; Single Nucleotide Polymorphisms

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; C REACTIVE PROTEIN; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; ATHEROSCLEROSIS; ATTRIBUTABLE RISK; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ETHNICITY; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 78249233853     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010030     Document Type: Article

References (87)

1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardio-vascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51: 1829-1843.
3. Kanjilal S, Shanker J, Rao VS, et al. Prevalence and component analysis of metabolic syndrome: an Indian atherosclerosis research study perspective. Vasc Health Risk Manag 2008; 4: 189-197.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979.
5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovas-cular disease in women. N Engl J Med 2000; 342: 836-843.
6. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138.
7. Ridker PM, Silvertown JD. Inflammation, C-reactive protein, and atherothrombosis. J Periodontol 2008; 79: 1544-1551.
8. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin ther-apy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
9. Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009; 55: 219-228.
10. Sattar N, Murray HM, McConnachie A, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115: 981-989.
11. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83: 456S-460S.
12. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
13. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137.
14. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
15. Biasucci LM, Liuzzo G, Colizzi C, Maseri A. The role of cytokines in unstable angina. Expert Opin Investig Drugs 1998; 7: 1667-1672.
16. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993; 126: 1299-304.
17. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem 2001; 47: 426-430.
18. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovas-cular disease. Circulation 2001; 103: 1813-1818.
19. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275: 18138-18144.
20. Humphries SE, Yiannakouris N, Talmud PJ. Cardiovascular dis-ease risk prediction using genetic information (gene scores): is it really informative? Curr Opin Lipidol 2008;19: 128-132.
21. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case-control study and meta-analysis. Hum Mol Genet 2006; 15: 1914-1920.
22. Maitra A, Shanker J, Dash D, et al. Polymorphisms in the IL6 gene in Asian Indian families with premature coronary artery disease--the Indian Atherosclerosis Research Study. Thromb Haemost 2008; 99: 944-950.
23. Bittar MN, Carey JA, Barnard J, et al. Interleukin 6 G-174C poly-morphism influences outcome following coronary revascularization surgery. Heart Surg Forum 2005; 8: 140-145; discussion E145.
24. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene-174g>c and-572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458-1463.
25. Georges JL, Loukaci V, Poirier O, et al. Interleukin-6 gene poly-morphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Temoin de l'Infarctus du Myocarde. J Mol Med 2001; 79: 300-305.
26. Basso F, Lowe GD, Rumley A, McMahon AD, Humphries SE. Interleukin-6-174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WO-SCOPS). Arterioscler Thromb Vasc Biol 2002; 22: 599-604.
27. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The inter-leukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001; 22: 2243-2252.
28. Sie MP, Mattace-Raso FU, Uitterlinden AG, et al. The interleukin-6-174 G/C promoter polymorphism and arterial stiffness; the Rot-terdam Study. Vasc Health Risk Manag 2008; 4: 863-869.
29. Mostafazadeh A, Herder C, Haastert B, et al. Association of hu-moral immunity to human Hsp60 with the IL-6 gene polymorphism C-174G in patients with type 2 diabetes and controls. Horm Metab Res 2005; 37: 257-263.
30. Greisenegger S, Zehetmayer S, Bauer P, et al. Polymorphisms in inflammatory genes and the risk of ischemic stroke and transient ischemic attack: results of a multilocus genotyping assay. Clin Chem 2009; 55: 134-138.
31. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004; 27: 813-823.
32. Rauramaa R, Vaisanen SB, Luong LA, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657-2662.
33. Libra M, Signorelli SS, Bevelacqua Y, et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial dis-ease. J Clin Pathol 2006; 59: 211-215.
34. Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000; 85: 1334-1339.
35. Lieb W, Pavlik R, Erdmann J, et al. No association of interleukin-6 gene polymorphism (-174 G/C) with myocardial infarction or traditional cardiovascular risk factors. Int J Cardiol 2004; 97: 205-212.
36. Sekuri C, Cam FS, Sagcan A, et al. No association of interleukin-6 gene polymorphism (-174 G/C) with premature coronary artery disease in a Turkish cohort. Coronary Artery Dis 2007; 18: 333-337.
37. Tso AR, Merino JG, Warach S. Interleukin-6 174G/C polymor-phism and ischemic stroke: a systematic review. Stroke 2007; 38: 3070-5.
38. Fu HX, Zhang JY, Li GS, Li Y, Xu JL, Zhao ZN. Study on linkage between polymorphism of interleukin 6 gene-572C/G and suscep-tibility to myocardial infarction. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23: 245-249.
39. Wei YS, Lan Y, Liu YG, Tang RG, Lan JS. Relationship between interleukin-6 gene polymorphism and coronary heart disease and its effect on plasma lipid levels. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006; 18: 233-236.
40. Jang Y, Kim OY, Hyun YJ, et al. Interleukin-6-572C>G polymor-phism-association with inflammatory variables in Korean men with coronary artery disease. Transl Res 2008; 151: 154-161.
41. Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE. Interleukin-6 promoter haplotypes and interleukin-6 cytokine re-sponses. Shock 2003; 20: 218-223.
42. Carlson CS, Aldred SF, Lee PK, et al. Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77: 64-77.
43. Dupuis J, Larson MG, Vasan RS, et al. Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q. Atherosclerosis 2005; 182: 307-314.
44. Pankow JS, Folsom AR, Cushman M, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681-689.
45. Kathiresan S, Larson MG, Vasan RS, et al. Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to inter-individual variability in serum C-reactive protein level. Circulation 2006; 113: 1415-1423.
46. Crawford DC, Sanders CL, Qin X, et al. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 2006; 114: 2458-2465.
47. Evrim KB, Nihan EU, Altan O, et al. Association of C-reactive protein (CRP) gene allelic variants with serum CRP levels and hy-pertension in Turkish adults. Atherosclerosis 2009; 206(2): 474-479.
48. Wang Q, Ding H, Tang JR, et al. C-reactive protein polymorphisms and genetic susceptibility to ischemic stroke and hemorrhagic stroke in the Chinese Han population. Acta Pharmacol Sin 2009; 30: 291-298.
49. Morita A, Nakayama T, Doba N, Hinohara S, Soma M. Polymor-phism of the C-reactive protein (CRP) gene is related to serum CRP Level and arterial pulse wave velocity in healthy elderly Japa-nese. Hypertens Res 2006; 29: 323-331.
50. Teng MS, Hsu LA, Wu S, Chang HH, Chou HH, Ko YL. Associa-tion between C-reactive protein gene haplotypes and C-reactive protein levels in Taiwanese: interaction with obesity. Atherosclerosis 2009; 204: 64-69.
51. Martinez-Calatrava MJ, Gonzalez-Sanchez JL, Martinez-Larrad MT, Perez-Barba M, Serrano-Rios M. Common haplotypes of the C-reactive protein gene and circulating leptin levels influence the interindividual variability in serum C-reactive protein levels. The Segovia study. Thromb Haemost 2007; 98: 1088-1095.
52. Paik JK, Kim OY, Koh SJ, et al. Additive effect of interleukin-6 and C-reactive protein (CRP) single nucleotide polymorphism on serum CRP concentration and other cardiovascular risk factors. Clin Chim Acta 2007; 380: 68-74.
53. Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53: 1029-1034.
54. Wong LY, Leung RY, Ong KL, Cheung BM. Plasma levels of fibrinogen and C-reactive protein are related to interleukin-6 gene-572C>G polymorphism in subjects with and without hypertension. J Hum Hypertens 2007; 21: 875-882.
55. Ridker PM, Pare G, Parker A, et al. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet 2008; 82: 1185-1192.
56. Reiner AP, Barber MJ, Guan Y, et al. Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet 2008; 82: 1193-201.
57. Jeng JR. Plasma C-reactive protein and 5-lipoxygenase-activating protein gene promoter poly-A polymorphism in patients with coro-nary artery disease. Cardiology 2008; 109: 25-32.
58. Allen RA, Lee EM, Roberts DH, Park BK, Pirmohamed M. Polymorphisms in the TNF-alpha and TNF-receptor genes in pa-tients with coronary artery disease. Eur J Clin Invest 2001; 31: 843-851.
59. Koch W, Kastrati A, Bottiger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene poly-morphisms and risk of coronary artery disease and myocardial in-farction. Atherosclerosis 2001; 159: 137-144.
60. Pereira TV, Rudnicki M, Franco RF, Pereira AC, Krieger JE. Effect of the G-308A polymorphism of the tumor necrosis factor alpha gene on the risk of ischemic heart disease and ischemic stroke: a meta-analysis. Am Heart J 2007; 153: 821-830.
61. Sbarsi I, Falcone C, Boiocchi C, et al. Inflammation and athero-sclerosis: the role of TNF and TNF receptors polymorphisms in coronary artery disease. Int J Immunopathol Pharmacol 2007; 20: 145-154.
62. Sookoian SC, Gonzalez C, Pirola CJ. Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome. Obes Res 2005; 13: 2122-2131.
63. Corbalan MS, Marti A, Forga L, Patino A, Martinez-Gonzalez MA, Martinez JA. Influence of two polymorphisms of the tumoral ne-crosis factor-alpha gene on the obesity phenotype. Diabetes Nutr Metab 2004; 17: 17-22.
64. Dalziel B, Gosby AK, Richman RM, Bryson JM, Caterson ID. Association of the TNF-alpha-308 G/A promoter polymorphism with insulin resistance in obesity. Obes Res 2002; 10: 401-407.
65. Lakka HM, Lakka TA, Rankinen T, et al. The TNF-alpha G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study. Vasc Pharmacol 2006; 44: 377-383.
66. Morange PE, Tregouet DA, Godefroy T, et al. Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha convert-ing enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. J Mol Med 2008; 86: 1153-1161.
67. Mälarstig A, Eriksson P, Rose L, et al. Genetic variants of tumor necrosis factor superfamily, member 4 (TNFSF4), and risk of incident atherothrombosis and venous thromboembolism. Clin Chem 2008; 54: 833-840.
68. Zee RY, Hennessey H, Michaud SE, Ridker PM. Genetic variants within the interleukin-1 gene cluster, and risk of incident myocar-dial infarction, and ischemic stroke: a nested case-control approach. Atherosclerosis 2008; 201(1): 124-129.
69. Grisoni ML, Proust C, Alanne M, et al. Lack of association between polymorphisms of the IL18R1 and IL18RAP genes and cardiovascular risk: the MORGAM Project. BMC Med Genet 2009; 10: 44.
70. Vohnout B, Di Castelnuovo A, Trotta R, et al. Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease. Haema-tologica 2003; 88: 54-60.
71. Iacoviello L, Di Castelnuovo A, Gattone M, et al. Polymorphisms of the interleukin-1beta gene affect the risk of myocardial infarc-tion and ischemic stroke at young age and the response of mononu-clear cells to stimulation in vitro. Arterioscler Thromb Vasc Biol 2005; 25: 222-227.
72. Everett BM, Bansal S, Rifai N, Buring JE, Ridker PM. Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 2009; 202: 282-8.
73. Anguera I, Miranda-Guardiola F, Bosch X, et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002; 144: 811-817.
74. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001;104: 746-749.
75. Erdmann J, Grosshennig A, Braund PS, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet 2009; 41: 280-282.
76. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009; 41: 334-341.
77. Samani NJ, Deloukas P, Erdmann J, et al. Large scale association analysis of novel genetic loci for coronary artery disease. Arterioscler Thromb Vasc Biol 2009; 29: 774-780.
78. Trégouët DA, König IR, Erdmann J, et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 2009; 41: 283-285.
79. Ruchat SM, Despres JP, Weisnagel SJ, Chagnon YC, Bouchard C, Perusse L. Genome-wide linkage analysis for circulating levels of adipokines and C-reactive protein in the Quebec family study (QFS). J Hum Genet 2008; 53: 629-636.
80. Lakka TA, Rankinen T, Rice T, et al. Quantitative trait locus on chromosome 20q13 for plasma levels of C-reactive protein in healthy whites: the HERITAGE Family Study. Physiol Genomics 2006; 27: 103-107.
81. Ding K, Feng D, de Andrade M, et al. Genomic regions that influence plasma levels of inflammatory markers in hypertensive sib-ships. J Hum Hypertens 2008; 22: 102-110.
82. Samani NJ, Braund PS, Erdmann J, et al. The novel genetic variant predisposing to coronary artery disease in the region of the PSRC1 and CELSR2 genes on chromosome 1 associates with serum cho-lesterol. J Mol Med 2008; 86: 1233-1241.
83. Kleemann R, Verschuren L, van Erk MJ, et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol 2007; 8: R200.
84. Fernandez-Real JM, Broch M, Vendrell J, et al. Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 2000; 49: 517-520.
85. Grammer TB, Marz W, Renner W, Bohm BO, Hoffmann MM. C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LU-RIC study. Eur Heart J 2009; 30: 170-182.
86. Wang Q, Hunt SC, Xu Q, et al. Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study. Am J Physiol Heart Circ Physiol 2006; 291: H2752-757.
87. Andersson J, Johansson L, Ladenvall P, et al. C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study. Cerebrovasc Dis 2009; 27: 544-551.